MINNEAPOLIS, March 21, 2023 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, announced detailed preliminary results of the […]
Tag: Barostim
CVRx Launches a new Barostim™ Programmer
The new Barostim Programmer launches in the U.S., making Barostim therapy programming simpler and enabling remote view access to enhance customer support MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation […]
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received […]
BAROSTIM™ NEO Associated with Very High Responder Rates in Women
BeAT-HF Trial Results Presented as Late-Breaking Clinical Science at ESC Heart Failure 2020 Meeting MINNEAPOLIS, June 23, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company, announced new BeAT-HF trial results from late-breaking clinical science presented virtually at the European Society […]
Recent
New Data Demonstrates Vektor Medical’s AI-Powered vMap Algorithm Achieves 91% Accuracy in Distinguishing Epicardial and Endocardial Ventricular Tachycardia, Markedly Surpassing Visual ECG Analysis
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Genomadix Inc. Enters into Collaboration with Mayo Clinic on Precision Medicine for Telestroke
Popular
- No commented posts yet